Article

New Tadalafil Tablets Granted FDA Approval

Glenmark's drug product is a generic equivalent to Eli Lilly’s Cialis Tablets.

Officials with the FDA have approved Glenmark Pharmaceuticals’ Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg.1

This drug product is a new generic equivalent to Eli Lilly’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg,1 which is indicated for erectile dysfunction and the treatment of benign prostatic hyperplasia.2

The most common adverse reactions (≥ 2%) for tadalafil are headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, and pain in limb.2

Sales data for the 12 month period ending November 2020, the Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market achieved annual sales of approximately $125.5 million.1

REFERENCES

  • Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg [news release]. Mumbai, India; December 31, 2020: Glenmark Pharmaceuticals. [email].
  • Cialis [prescribing information]. Indianapolis, IN; Eli Lilly & Company; 2018.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Phone call, pharmacist woman and writing on medicine checklist, customer service or virtual pharmacy support. Serious doctor with medical notes, health insurance documents and talking at help desk
© 2025 MJH Life Sciences

All rights reserved.